Shares of IPG Photonics plunged as much as 9.3% to $63.58 on November 5, hitting a fresh 52-week low, after a strong third-quarter earnings report was eclipsed by a disappointing fourth-quarter outlook. Q3 revenue of $287.5 million beat Wall Street's $283.4 million consensus by 1.5%, and adjusted EPS of $0.61 topped the $0.49 estimate by 24%. Yet the stock is selling off because what lies ahead matters more than what just happened — and what lies ahead looks softer.

  • China's Battery Boom Is Taking a Breather, and That Hits IPG's Biggest Growth Engine. Management said the softer Q4 outlook reflects a near-term slowdown in China battery capacity additions. China battery welding has been the primary revenue driver for four consecutive quarters of double-digit growth. The Q4 midpoint of $280 million represents a sequential decline from Q3 levels , and it came in 4.8% below analysts' consensus estimates of $294.2 million. When a company's single biggest growth catalyst cools, investors immediately question whether the broader recovery story still holds.

  • Analysts Are Slashing Targets, Signaling the Growth Story Needs a Reset. Bernstein cut its price target to $92 from $122 , while Needham lowered its target from $120 to $105 . Both maintained buy-equivalent ratings, but the magnitude of the cuts — 25% and 13% respectively — tells investors that prior growth assumptions were too generous. The stock now sits well below its 52-week high of $155.82 , having shed nearly 60% of its value from that peak.

  • A Tariff Tailwind Disappears at the Worst Time. Q3 profitability benefited from $5 million in net tariff refunds, while Q4 guidance assumes no meaningful repeat benefit.

Adjusted gross margin guidance of 37%–40% for Q4 compares unfavorably to Q3's 40.7%. Without that one-time boost and with lower revenue, operating leverage works in reverse: fixed costs eat into a smaller revenue base.

  • The Balance Sheet Is a Cushion, but Cash Alone Won't Reignite Growth. IPG ended Q3 with $926 million in cash and no debt , giving management ample firepower. Advanced Solutions revenue surged 33% year-over-year, driven by semiconductor and defense applications , and management expects the pending Lumibird Medical acquisition to add revenue in 2027. These are real diversification levers — but they remain small relative to the China battery engine that just decelerated. Until investors see proof that semiconductors and defense can compensate at scale, the stock will trade on its weakest link.